Altogether, these results support the theory that empagliflozin treatment protects against the incipient nephropathy associated with the overexpression of the CRP transgene by reducing oxidative stress and inflammation either directly or as a consequence of reduced ectopic fat accumulation in the kidney. Here, CRP is linked to kidney disorder.